NCT06207175View on ClinicalTrials.gov

A Study to Evaluate the Immunogenicity and Safety of Nonavalent Human Papillomavirus (HPV) Vaccine

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

1,260

Participants

Timeline

Start Date

November 21, 2023

Primary Completion Date

November 17, 2024

Study Completion Date

January 25, 2026

Conditions
Human Papillomavirus Infection
Interventions
BIOLOGICAL

Nonavalent HPV study vaccine

A 3-dose regimen administered at months 0, 2 and 6.

BIOLOGICAL

GARDASIL® 9

A 3-dose regimen administered at months 0, 2 and 6.

Trial Locations (1)

Unknown

University of Muhammadiyah Malang Hospital, Malang

Sponsors
All Listed Sponsors
collaborator

University of Muhammadiyah Malang Hospital

UNKNOWN

collaborator

Dr. M Djamil Hospital, Padang

UNKNOWN

lead

Beijing Health Guard Biotechnology, Inc

INDUSTRY